Last reviewed · How we verify
DBPR108
DBPR108 is a small-molecule inhibitor that targets pyruvate dehydrogenase kinase (PDK) to modulate cellular metabolism and energy production.
DBPR108 is a small-molecule inhibitor that targets pyruvate dehydrogenase kinase (PDK) to modulate cellular metabolism and energy production. Used for Mitochondrial disease or metabolic disorders (Phase 3 development).
At a glance
| Generic name | DBPR108 |
|---|---|
| Sponsor | National Health Research Institutes, Taiwan |
| Drug class | Pyruvate dehydrogenase kinase (PDK) inhibitor |
| Target | PDK (Pyruvate Dehydrogenase Kinase) |
| Modality | Small molecule |
| Therapeutic area | Metabolic disorders / Mitochondrial dysfunction |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDK, DBPR108 allows pyruvate dehydrogenase (PDH) to remain active, promoting oxidative metabolism of pyruvate and shifting cellular energy utilization. This metabolic modulation is intended to improve mitochondrial function and reduce lactate accumulation, potentially benefiting conditions characterized by metabolic dysfunction or impaired energy metabolism.
Approved indications
- Mitochondrial disease or metabolic disorders (Phase 3 development)
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment (PHASE1)
- A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (PHASE3)
- A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment (PHASE1)
- A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients (PHASE1)
- A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects (PHASE1)
- Mass Balance and Biotransformation Study of [14C]DBPR108 in Human (PHASE1)
- A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DBPR108 CI brief — competitive landscape report
- DBPR108 updates RSS · CI watch RSS
- National Health Research Institutes, Taiwan portfolio CI